| |  |
| |
| Through The Reimbursement Barriers
| Brian Lovatt looks at how drug companies involved in oncology can meet their pricing and reimbursement objectives as NICE-style barriers start to rise across Europe. | | | Streamlining Synergies
| | Discussing the importance of post-merger integration and synergy management in the generics industry. | | | A Year in Pharma
| | Sarah Houlton outlines the deals, collaborations and controversies that shaped the pharmaceutical industry in 2007, and examines how the land lies as we prepare for 2008. | | | Understanding the Chinese Market
| | China's pharmaceutical market place may have been booming of late, but companies wishing to sustain growth in the country must ensure their intelligence is up to the minute, report Songjun Luo and Brian Chapman. | | | The Middleweight Challenge
| | Pfizer, Pfizer, Pfizer. Depending on your point of view, it's ironic, inspiring, or merely interesting that the company that staggered out of 2006 with its every vulnerability and vanity exposed in the media glare nonetheless finishes in Pharm Exec's winner's circle once again. | | | Staying Lucky
| | Over the past four decades, Ireland has developed a thriving pharmaceutical sector, thanks to a government policy designed to promote inward investment. It is now the world's largest net exporter of pharmaceuticals, with 29 plants approved by the US FDA. Initial pharma manufacturing operations in the 1960s focused on primary manufacture, and formulation into finished dosage forms followed later. However, as costs rise and it is becoming ever cheaper to manufacture medicines in places such as India and China, the country is trying hard to move up the value chain, into research and development. | |
| CEOs see pay increases in 2006
| | CEOs saw considerable increases in the value of their unexercised stock options last year, with chief executives at higher-performing companies seeing particularly large gains, according to a new CEO pay analysis by Watson Wyatt. | | | The Pharmaceutical Industry in Germany
| | German pharma has taken a slight upward swing of late, according to the German Association of Research-based Pharmaceutical Companies (Verband Forschender Arzneimittelhersteller [VFA]). The country was the world's most active market for mergers and acquisitions in 2006 (the first nine months of 2005 saw 35 transactions with a value of more than $7 billion); VFA member companies were able to increase their employees by about 1000; and funds spent by research-based pharmaceutical companies on R&D increased to exceed the €4 billion limit for the first time. | | | Nothing Ventured...
| | There is a much more aggressive and visionary stance taken by the industry to acquire new products and technologies developed by venture-backed start-ups. | |  MORE ARTICLES
|
| |
| Establishing Clinical Trials in China
| China's appeal as a location for clinical trials is well documented, but there are some hurdles to clear before a pharma company can successfully tap into its resources. | | | A New Europe for CROs
| | Alan Morgan offers an overview of Europe's rapidly evolving CRO landscape. | | | A Year in Pharma
| | Sarah Houlton outlines the deals, collaborations and controversies that shaped the pharmaceutical industry in 2007, and examines how the land lies as we prepare for 2008. | | | Due Pharmacovigilance
| | Increased investment in pharmacovigilance can maximise your portfolio value. | | | A Vision of 2020
| | The global pharmaceutical market is set to double in value by 2020. But the industry must transform itself if it is to capitalize on the forthcoming opportunities, says Steve Arlington. | | | The Biotech Supremacy
| | The US may still be leading the world pharma race, but a recent survey shows that innovation in biotechnology has secured the UK's position as the number two place to conduct pharmaceutical research. Martyn Postle reports. | | | Understanding the Chinese Market
| | China's pharmaceutical market place may have been booming of late, but companies wishing to sustain growth in the country must ensure their intelligence is up to the minute, report Songjun Luo and Brian Chapman. | | | The Road Less Travelled
| | Accurately predicting the future success of a novel therapeutic compound in today's burgeoning oncology market is perhaps best achieved by consulting a really good crystal ball. Alternatively, R&D managers can plot a drug's strengths and weaknesses against the emerging universe of insights into the molecular basis of disease and factor in the challenges of increasingly rigorous data review, high drug development price tags, unpredictable development timelines, and a wary post-launch reception from cost-cutting reimbursement regulators in every major pharmaceutical market. | | | Staying Lucky
| | Over the past four decades, Ireland has developed a thriving pharmaceutical sector, thanks to a government policy designed to promote inward investment. It is now the world's largest net exporter of pharmaceuticals, with 29 plants approved by the US FDA. Initial pharma manufacturing operations in the 1960s focused on primary manufacture, and formulation into finished dosage forms followed later. However, as costs rise and it is becoming ever cheaper to manufacture medicines in places such as India and China, the country is trying hard to move up the value chain, into research and development. | | | MORE ARTICLES
|
| |
| |
| |
| Due Pharmacovigilance
| | Increased investment in pharmacovigilance can maximise your portfolio value. | | | Data Expectations
| | Internet-based study communications systems should supply more than just reports. | | | Let's Get Digital
| | Lynn O'Connor Vos reflects on why embracing the digital communications revolution requires not just a whole new mindset, but a whole new set of skills. | | | Seizing Control
| | Although acheiving control and visibility of indirect spend can be a challenge, eProcurement systems can facilitate significant savings. | | | Getting ROI From IT
| | Ed Arnett outlines the things a company should consider before embarking on a programme of IT training. | |
| | Foiling the Fakers
| | Roland Meylan looks at the latest developments in anti-counterfeiting technology. | | | Courting Consolidation
| | With consolidated distribution gaining a significant foothold, particularly on the UK market, Colin Walsh looks at its implications on the pharma supply chain as it is rolled out across Europe. | | | Maximise Your Outsourcing Benefits
| | AstraZeneca is to begin outsourcing its manufacturing... what are the best ways for other companies to follow their example? | | | Getting the Message
| | In a noisy market, how do you ensure your voice is heard? That's the challenge for every brand manager, of course, but it's particularly acute in the pharmaceutical industry, where guaranteeing a positive reception is not just a case of shouting loudest or spending the greatest advertising budget. | | | MORE ARTICLES
|
| |
| Taking Back Control
| | Individual perceptions, word-of-mouth and the media create new meanings and sometimes mutilate the hard work of the brand marketer. | | | The Road Less Travelled
| | Accurately predicting the future success of a novel therapeutic compound in today's burgeoning oncology market is perhaps best achieved by consulting a really good crystal ball. Alternatively, R&D managers can plot a drug's strengths and weaknesses against the emerging universe of insights into the molecular basis of disease and factor in the challenges of increasingly rigorous data review, high drug development price tags, unpredictable development timelines, and a wary post-launch reception from cost-cutting reimbursement regulators in every major pharmaceutical market. | | | Growing Pains
| | Lift your head above the detail of your own product and company problems and look at the industry press. A remarkably consistent set of signals emerges. Redundancies, slower growth and thinner R&D pipelines all point to an industry that, whilst not in decline, is struggling to maintain the halcyon days of its youth. | | | Taking your Brand's Temperature
| | One of the great truisms in life is that it is better to prevent than it is to treat. And the concept of prevention is becoming increasingly important to our customers, with regard to how they view certain conditions, such as obesity. If we can see what might be going wrong in the first place, it is far easier to act to prevent damage than to wait until disaster strikes and then try to repair it. So, when it comes to marketing brands, why, once we have spent significant time and effort developing them, do we often ignore the signs that all is not well? | |
| Brand not Bland
| | The last decade or so has seen the major pharmaceutical companies grow and grow. Through mergers and acquisitions, the big guys have got bigger and bigger and a huge number of the little guys have been swallowed up in the process. The same has happened with the big communications networks like IPG, Omnicom and WPP, as they have acquired small- to medium-sized independent agencies in an attempt to complete their European coverage to meet their individual client needs. | | | The Power of Podcasting
| | Podcasts allow marketers to be creative using a flexible, ubiquitous and quick information delivery format. | | | Stimulating Innovation
| | Making good quality medicines available at relatively low prices is a pretty noble thing. | | | Building a Stronger Supply Chain
| | Driving to launch a new drug barely leaves time to do just the essential things. Although the focus on trial recruitment, file submission and package presentation is key, it can drive out other activities that are equally important to the continued success of your drug. This includes the development of an efficient supply chain. | | | Big Pharma Strikes Back
| | The recent battle between Merck and Teva is yet another expression of the ongoing breakdown of the Industry's traditional business structures and practices. It also means that traditional intellectual property (IP) and pricing models are changing as we speak. This time, however, it is the generics companies that could remain with the shorter end of the stick. | | | MORE ARTICLES
|
| |
| Anti-counterfeiting in Europe: a breakthrough?
| | The EU finally is finally starting a new battle in the war against drug counterfeiting, reports Pharm Exec Europe columnist Reflector. | | | Animal Traps
| | How will the long-threatened revision of the EU's twenty-year old legislation on animal testing affect the industry? | | | Trust or Bust
| | Reflector ponders the good, the bad and the ugly aspects of the EU's antitrust investigations. | | | Trust or Bust
| | Reflector ponders the good, the bad and the ugly aspects of the EU's anti-trust investigations. | | | Happy New Euro?
| | As two more countries sign up for the euro, Reflector pierces the New Year mist in Brussels to look at just what a common currency means for European pharma. | | | Great Expectations?
| | The regulators are full of good ideas when it comes to new initiatives, but the industry knows better than to expect any real advances. Reflector reports on the EIT and the IMI, the latest proposals struggling to leave the launching pad. | | | Giving with One Hand, Taking with the Other
| | The EU gives boost to advanced therapies, but deals blow to GMOs | | | Animal Passions
| | Both pharma and the animals it tests on are keen to escape the 'cages' that constrain them. But the industry-vs-activists debate intensifies at every turn of the key, says Reflector. | | | The Holiday's Over
| | ...the EMEA and the European Commission have at last publicly admitted what industry has been saying for years — that Europe's clinical trials legislation is not working as designed. | | | MORE ARTICLES
|
| |
| News & Analysis
| | News & Analysis | | | 26-JUN-07: BPE 07 date announced
| | The 15th Annual BioPartnering Europe conference (BPE) is to be held in London, England on October 7–9, 2007. | | | Calendar
| | Calendar | | | Calendar
| | Success in the pharmaceutical industry depends on the speed and efficiency of new drug approvals. This process largely relies on the quality of documentation submitted to the regulatory authorities, and a high standard of medical writing plays a vital role in ensuring success. This intensive practical medical writing course will benefit participants by enabling them to achieve this standard. | | | Calendar
| | With a focus on data mining and analysis, this year's programme (following 2005's "Signal Detection, Evaluation and Tracking") addresses the techniques and tools available to analyse signals and back-up decisions, with an emphasis on risk management, drug safety and epidemiology. The event features three workshops and participation from Roche, Bayer, Sanofi-Aventis and Procter & Gamble. | | | Calendar
| | For anyone who now has, or plans to have, manufacturing facilities in the US, this event offers a comprehensive exploration of everything from process validation to computer systems validation. | | | Calendar
| | BioBusiness is a senior-level biopartnering conference, designed specifically for both pharma companies looking for high-quality assets to in-license or partner with, and small biotechs in need of funding, outlicensing and partnering opportunities. | | | MORE ARTICLES
|
| |
| A New Europe for CROs
| | Alan Morgan offers an overview of Europe's rapidly evolving CRO landscape. | | | 9-AUG-07: Perceptive updates IMPACT
| | Perceptive Informatics (US), the technology subsidiary of PAREXEL International Corporation (US), has announced the release of an enhanced version of its comprehensive clinical trial management system (CTMS) IMPACT technology. | | | Adaptive Trial Design
| | An adaptive clinical trial is defined as a study that includes a sequence of interim analyses to enable sponsors to modify the course of a trial dynamically. The earliest and simplest forms of adaptive trials were those where interim analyses were used to stop trials early, because of overwhelming (and statistically significant) evidence of efficacy. | | | Staying Lucky
| | Over the past four decades, Ireland has developed a thriving pharmaceutical sector, thanks to a government policy designed to promote inward investment. It is now the world's largest net exporter of pharmaceuticals, with 29 plants approved by the US FDA. Initial pharma manufacturing operations in the 1960s focused on primary manufacture, and formulation into finished dosage forms followed later. However, as costs rise and it is becoming ever cheaper to manufacture medicines in places such as India and China, the country is trying hard to move up the value chain, into research and development. | | | Picking Up The Pieces
| | Every component of the European pharmaceutical sector — industry, regulators, clinicians and academics — is going to spend the next few weeks in a desperate attempt to regain its respectability and rebuild confidence. In the latest crisis to hit the sector, the "blame the other guy" approach is likely to feature even more prominently than usual. So expect some starshells bursting over the usually sombre world of European Union consultations. | | | The Hub of the Wheel
| | According to popular myth, older elephants instinctively leave their group when they reach a certain age, and direct themselves to a special area known as the elephants' graveyard, where they die, alone and far from the group. There are those who believe that the elephants' graveyard is an accurate analogy for regulatory affairs in the pharma industry, where old, exhausted R&D folk migrate over to Regulatory for their last few years before retirement. | | | Optimizing Phase III Trials
| | By involving members of the relevant groups as required, each workshop can extract information to match the interests of all of these stakeholders. | | | News & Analysis
| | Pfizer's ousted chief executive has left with a controversial financial package totalling up to $200 million. In a filing with the US Securities and Exchange Commission, Pfizer noted that Henry (Hank) McKinnell, who stepped down as chief executive in July 2006, will receive over $180 million consisting of stock totalling more than $20.7 million, $77.9 million in deferred compensation and cash, and an estimated $82.3 million in pension benefits (an annual payment of $6.6 million for the rest of McKinnell's life). Contingent on future stock performance, McKinnell could also receive up to an additional $18.3 million stock award. | | | News & Analysis
| | The wrangle over the unexpected generic version of Sanofi-Aventis' blood-thinning agent Plavix (clopidogrel) is set to continue, after a US court granted the company, and its US marketing partner Bristol-Myers Squibb (BMS), an injunction blocking Apotex's rival product. | | | MORE ARTICLES
|
| |
| FCB HealthCare
| | Foote Cone & Belding (FCB) was founded as Lord & Thomas in 1873 and became Foote Cone & Belding in 1943 when its top managers, Emerson Foote, Fairfax Cone and Don Belding, acquired the agency. | | | Performance Design, Inc.
| | Want to launch a Global Selling Skills Curriculum fast? | | | Cegedim
| | Founded in 1969, Cegedim quickly became Europe's leading supplier of sales and marketing data for pharmaceutical companies. Years of partnering with the world's largest healthcare companies have resulted in a unique relationship of trust, mutual understanding and shared development. Today, Cegedim operates throughout the world and provides sales and marketing effectiveness solutions for the pharmaceutical industry. | | | Etrials Worldwide
| | Etrials is an eClinical technology and services company dedicated to making eClinical easy. | | | Kendle
| | Kendle (Nasdaq: KNDL) is among the world's leading global clinical research organizations. We deliver innovative and robust clinical development solutions — from first-in-human studies through market launch and surveillance — to help the world's biopharmaceutical companies maximize product life cycles and grow market share. With the expertise of our more than 1800 associates worldwide, we have conducted clinical trials or provided regulatory, pharmacovigilance and validation services in 70 countries. We have conducted Phase III studies for eight of the top 10 biopharmaceutical companies worldwide. | | | Sudler & Hennessey
| | Sudler & Hennessey | | | Excerpta Medica
| | Excerpta Medica, an Elsevier business, is a global medical communications company with headquarters in The Netherlands and the US. At Excerpta Medica, we bring an experienced team of professionals from healthcare and publishing to partner with our clients in the delivery of strategic communications solutions across all media. | | | LibraPharm Ltd
| | LibraPharm is an independent publishing and communications company offering innovative solutions to meet the information needs of professionals in the medical, pharmaceutical and biotechnology sectors worldwide. | | | IMS Health
| | IMS is the world's leading provider of business intelligence and strategic consulting services for the pharmaceutical and healthcare industries. Operating in more than 100 countries, we apply evidence-based intelligence — combining the best global healthcare infor |
|
|
|
| 
